Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study
MedScience · 2026
DOI: 10.1007/s11684-026-1200-8 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift MedScience, 2026. Verfasst von Yuting Yan und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Lymphoma, B-Cell. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
This study evaluated the efficacy and safety of obinutuzumab plus bendamustine (GB) as first-line treatment for indolent B-cell lymphomas. In this prospective, multicenter, single-arm trial (NCT06415708), adults with newly diagnosed indolent B-cell lymphomas-including follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), hairy cell leukemia variant (HCL-v), and unclassified B-cell lymphoproliferative disorder (BCLPD-U)-received six induction cycles of GB followed by 2 years of obinutuzumab maintenance in responders (⩾ partial response). The primary endpoint was overall response rate (ORR), whereas secondary endpoints included complete response rate (CRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Among 220 enrolled patients (149 with FL and 71 with non-FL), 210 completed ⩾ 3 treatment cycles. At a median follow-up of 13.1 months, ORRs in the different patient subgroups were 96.6% (FL), 100% (MZL, HCL-v), 92.9% (WM), and 88.9% (BCLPD-U). The median DOR was 16.7 months in the FL group and was not reached in the non-FL group. PFS and OS were not reached in any subgroup. The FL and non-FL groups had comparable ORRs (P = 0.435); however, the FL group showed a higher CRR (92.4% vs. 78.5%; P = 0.004) and shorter PFS (P = 0.020). Treatment-emergent adverse events occurred in 42 patients and were more frequent in the non-FL group than in the FL group (26.8% vs. 15.4%; P = 0.046), particularly infections (18.3% vs. 6.0%; P = 0.005). Overall, the GB regimen demonstrated high response rates and manageable safety in Chinese patients with indolent B-cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, 301600, China.
- GCP Administration Office, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, China.
- The Second Hospital of Dalian Medical University, Dalian, 116021, China.
- Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400038, China.
- Tianjin Medical University General Hospital, Tianjin, 300041, China.
Zitieren
APA
Yan, Y., Hu, X., Sun, X., Xiang, X., Wang, Y., Wang, T., Zhang, K., Wang, L., Jia, Y., Gui, C., Yu, Y., Lyu, R., Xiong, W., Deng, S., Liu, W., Huang, L., An, G., Qiu, L., Yi, S., & Chinese Workshop of Indolent Lymphomas (2026). Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study. MedScience. https://doi.org/10.1007/s11684-026-1200-8
Vancouver
Yan Y, Hu X, Sun X, Xiang X, Wang Y, Wang T, et al. Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study. MedScience. 2026. doi:10.1007/s11684-026-1200-8
BibTeX
@article{Yan2026,
author = {Yan, Yuting and Hu, Xinyang and Sun, Xiuhua and Xiang, Xixi and Wang, Yihao and Wang, Tingyu and Zhang, Kejie and Wang, Liang and Jia, Youchao and Gui, Chengsi and Yu, Ying and Lyu, Rui and Xiong, Wenjie and Deng, Shuhui and Liu, Wei and Huang, Liang and An, Gang and Qiu, Lugui and Yi, Shuhua and Chinese Workshop of Indolent Lymphomas, Chinese Workshop of Indolent Lymphomas},
title = {Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study},
journal = {MedScience},
year = {2026},
doi = {10.1007/s11684-026-1200-8}
}
EUVIMED